Publications by authors named "Daniel S W Tan"

74Publications

Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.

Oral Oncol 2020 Oct 19;111:105035. Epub 2020 Oct 19.

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610, Singapore; SingHealth Duke-NUS Oncology Academic Clinical Programme, SingHealth Duke-NUS Medical School, 8 College Rd, Singapore 169857, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.105035DOI Listing
October 2020

Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer.

N Engl J Med 2020 09;383(10):944-957

From the Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne and University of Cologne, Cologne (J.W.), Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg, Heidelberg (M.T.), the Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen (T.R.O.), and Hämato-Onkologie Hamburg, Hamburg (E.L.) - all in Germany; the National Hospital Organization Kyushu Cancer Center, Fukuoka (T.S.), Aichi Cancer Center, Nagoya (T.H.), the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.), the Department of Respiratory Medicine, Okayama University Hospital, Okayama (K.O.), and the National Kyushu Cancer Center, Fukuoka (R.T.) - all in Japan; the National Cancer Center, Gyeonggi-do (J.-Y.H.), and the Department of Internal Medicine, Seoul National University Hospital, Seoul (T.-M.K.) - both in South Korea; the Hospital Clinic of Barcelona (N.R.), Translational Genomic and Targeted Therapeutics in Solid Tumors (IDIBAPS) (N.R.), and Vall d'Hebron University Hospital-Vall d'Hebron Institute of Oncology (E.F.), Barcelona; David Geffen School of Medicine at UCLA, Los Angeles (E.B.G.); the University of Groningen and University Medical Center Groningen, Groningen (H.J.M.G.), Erasmus MC Cancer Institute, Rotterdam (M.J.), and the Netherlands Cancer Institute, Amsterdam (E.F.S.) - all in the Netherlands; the National Cancer Centre Singapore, Singapore (D.S.W.T.); St. Petersburg Pavlov State Medical University, St. Petersburg, Russia (S.V.O.); University Hospital of Lyon-Sud, Lyon (P.-J.S.), and Novartis Pharma, Rueil-Malmaison (S.L.M.) - both in France; the Respiratory Oncology Unit, University Hospitals KU Leuven, Leuven, Belgium (J.V.); the Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna (M.H.); the Thoracic Oncology Division, European Institute of Oncology, IRCCS, Milan (F.M.); Novartis Pharmaceuticals, East Hanover, NJ (A.R., M.G.); Novartis Pharma, Basel, Switzerland (M.W.-L., M.A.); and Novartis Institutes for BioMedical Research, Cambridge (B.S., O.A.B., X.C.), and Massachusetts General Hospital, Boston (R.S.H.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2002787DOI Listing
September 2020

Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC.

J Thorac Oncol 2020 Aug 28. Epub 2020 Aug 28.

Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.08.011DOI Listing
August 2020

Efficacy of Selpercatinib in -Altered Thyroid Cancers.

N Engl J Med 2020 08;383(9):825-835

From Massachusetts General Hospital (L.J.W.) and Dana-Farber Cancer Institute (J. Lorch), Boston; Memorial Sloan Kettering Cancer Center, New York (E.S., A.D.); Royal North Shore Hospital, St. Leonards, NSW (B.R.), and Peter MacCallum Cancer Institute, Melbourne, VIC (B.S.) - both in Australia; University of California, San Francisco-Helen Diller Family Comprehensive Cancer Center, San Francisco (H.K.), David Geffen School of Medicine at UCLA, Los Angeles (J.W.G.), and Chao Family Comprehensive Cancer Center, University of California Irvine, Orange (V.W.Z.) - all in California; University of Michigan, Ann Arbor (F.W.), and START Midwest, Grand Rapids (N.L.) - both in Michigan; University of Pennsylvania, Philadelphia (M.B.); University of Chicago, Chicago (J.P.); Gustave Roussy, Villejuif (S.L.), Institut Bergonié, Bordeaux (Y.G.), Aix Marseille University, Centre National de la Recherche Scientifique, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Early Phase Cancer Trial Center CLIP2, Hospital La Timone, Marseille (F.B.), Centre Léon Bérard, Lyon (C.D.L.F.), and Hôpital Européen Georges-Pompidou, Faculté de Médecine Paris-Descartes, Paris (J.M.) - all in France; Mayo Clinic-Rochester, Rochester, MN (J.C.M.); Winship Cancer Institute of Emory University, Atlanta (T.K.O.); National Cancer Center Singapore, Singapore (D.S.W.T.); University of Bern, Bern, and Cantonal Hospital of Lucerne, Lucerne - both in Switzerland (O.G.); University of North Carolina-Chapel Hill, Chapel Hill (J.W.); University of Wisconsin-Carbone Cancer Center, Madison (M.E.B.); British Columbia Cancer Agency, Vancouver, Canada (J. Laskin); Oregon Health and Science University, Portland (M.H.T.); Universitätsklinikum Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetology, Würzburg, Germany (M.K.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); Johns Hopkins Kimmel Cancer Center, Washington, DC (B.L.); Fundación Jimenez Diaz, START-Madrid, Madrid (V.M.); Loxo Oncology, Stamford, CT (K.E., M.N., D.H., E.Y.Z., X.H., L.Y., J.K., S.M.R.); University of Texas M.D. Anderson Cancer Center, Houston (V.S., M.E.C.); and Ohio State University Comprehensive Cancer Center, Columbus (M.H.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2005651DOI Listing
August 2020

Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2020 08;383(9):813-824

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D., E.R.) and New York University Langone Medical Center (V.V.), New York, and Roswell Park Comprehensive Cancer Center, Buffalo (G.K.D.) - all in New York; Dana-Farber Cancer Institute (G.R.O.) and Massachusetts General Hospital (J.G.), Boston; National Cancer Centre Singapore, Singapore (D.S.W.T.); the Chinese University of Hong Kong, Hong Kong, China (H.H.F.L.); Sarah Cannon Research Institute, Nashville (M.J.); University of California, San Francisco-Helen Diller Family Comprehensive Cancer Center, San Francisco (C.E.M.), University of California, San Diego, Moores Cancer Center, La Jolla (L.B.), and City of Hope Comprehensive Cancer Center, Duarte (K.L.R.) - all in California; University of Bern, Bern, and Cantonal Hospital of Lucerne, Lucerne - both in Switzerland (O.G.); Institut Gustave Roussy, Villejuif (B.B.), Hospital La Timone, Marseille (F.B.), and Centre Léon Bérard, Lyon (P.A.C.) - all in France; Severance Hospital, Yonsei University Health System (B.C.C.), and Samsung Medical Center, Sungkyunkwan University School of Medicine (K.P.), Seoul, and Seoul National University Bundang Hospital, Seongnam (Y.J.K.) - all in South Korea; Soroka University Medical Center, Beer-Sheva, Israel (N.P.); University of North Carolina-Chapel Hill, Chapel Hill (J. Weiss); National Cancer Center Hospital (Y.O.) and Cancer Institute Hospital of the Japanese Foundation for Cancer Research (M. Nishio), Tokyo, National Hospital Organization Kyushu Cancer Center, Fukuoka (T. Seto), Tottori University Hospital, Tottori (T. Sakamoto), Hyogo Cancer Center, Akashi (M.S.), Okayama University Hospital, Okayama (K.O.), and National Cancer Center Hospital East, Chiba (K.G.) - all in Japan; University of Chicago, Chicago (J.P.); the Ohio State University Comprehensive Cancer Center, Columbus (M.H.S.), and Cleveland Clinic, Cleveland (N.A.P.); Istituto Nazionale Tumori-National Cancer Institute, Università degli Studi di Milano, Milan (F.D.B.); Vall d'Hebron Institute of Oncology, Hospital Universitario Vall d'Hebron, Barcelona (E.G.); Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany (J. Wolf); Peter MacCallum Cancer Institute, Melbourne, VIC, Australia (B.S.); Sarah Cannon Research Institute at HealthONE, Denver (G.F.); Loxo Oncology, Stamford, CT (K.E., M. Nguyen, B.N., E.Y.Z., L.Y., X.H., E.O., S.M.R.); and the University of Texas M.D. Anderson Cancer Center, Houston (V.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2005653DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506467PMC
August 2020

High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade.

Int J Radiat Oncol Biol Phys 2020 Sep 13;108(1):70-80. Epub 2020 Jun 13.

Division of Radiation Oncology, National Cancer Centre Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore; Division of Medical Sciences, National Cancer Centre Singapore, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2020.06.007DOI Listing
September 2020

Challenges and insights of early phase oncology drug development in the Asia-Pacific region.

Chin Clin Oncol 2019 Jun;8(3):26

National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/26545/24274
Publisher Site
http://dx.doi.org/10.21037/cco.2019.06.02DOI Listing
June 2019

Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC).

Expert Rev Anticancer Ther 2019 06 14;19(6):431-435. Epub 2019 Apr 14.

a Division of Medical Oncology , National Cancer Centre Singapore , Singapore , Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1604228DOI Listing
June 2019

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 11 29;36(31):3101-3109. Epub 2018 Aug 29.

Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Li Zhang, Sun Yat-sen University Cancer Center, Guangdong; Xiaoqing Liu, Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing; Sylvia Zhao and Bin Peng, Novartis Institutes for Biomedical Research, Shanghai, People's Republic of China; Dong-Wan Kim, Seoul National University Hospital; Dae Ho Lee, University of Ulsan College of Medicine; Myung-Ju Ahn, Samsung Medical Center, Seoul, Republic of Korea; James Chih-Hsin Yang, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Johan F. Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Vincent Chia and Philippe Pultar, Novartis Pharmaceuticals, East Hanover, NJ; Sabine Glaser and Mikhail Akimov, Novartis Pharma AG, Basel, Switzerland; and Daniel S.W. Tan, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.7326DOI Listing
November 2018

Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer.

Transl Lung Cancer Res 2018 Feb;7(Suppl 1):S13-S18

Division of Medical Oncology, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2017.11.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835622PMC
February 2018

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Nat Rev Clin Oncol 2018 03 14;15(3):151-167. Epub 2017 Nov 14.

National Cancer Center, 11 Hospital Drive, Singapore 169610, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.175DOI Listing
March 2018

Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

Ann Transl Med 2017 Sep;5(18):372

Division of Medical Oncology, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2017.08.42DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635263PMC
September 2017

Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade.

Authors:
Daniel S W Tan

J Clin Oncol 2017 08 17;35(24):2735-2736. Epub 2017 Jul 17.

Daniel S.W. Tan, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.6215DOI Listing
August 2017

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Cancer Treat Rev 2017 Apr 30;55:181-189. Epub 2017 Mar 30.

University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.006DOI Listing
April 2017

Novel therapeutic targets on the horizon for lung cancer.

Lancet Oncol 2016 08;17(8):e347-e362

Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Cancer Therapeutics Research Laboratory, National Cancer Centre Singapore, Singapore; Genome Institute of Singapore, A*STAR, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30123-1DOI Listing
August 2016

Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer.

J Mol Diagn 2016 05 9;18(3):416-424. Epub 2016 Mar 9.

Genome Institute of Singapore, Singapore; Cancer & Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School, Singapore; Cancer Science Institute Singapore, National University of Singapore, Singapore; Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2016.01.006DOI Listing
May 2016

Microfluidic enrichment for the single cell analysis of circulating tumor cells.

Sci Rep 2016 Feb 29;6:22076. Epub 2016 Feb 29.

Department of Biomedical Engineering, National University of Singapore, 4 Engineering Drive 3, Block E4, #04-08, Singapore 117583, Singapore.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/srep22076
Publisher Site
http://dx.doi.org/10.1038/srep22076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770429PMC
February 2016

Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography.

J Clin Oncol 2016 Jan 17;34(1):91-101. Epub 2015 Nov 17.

Daniel S.W. Tan, National Cancer Centre Singapore and Genome Institute of Singapore, Singapore; Tony S.K. Mok, The Chinese University of Hong Kong, Sir Y. K. Pau Cancer Center, State Key Laboratory of Southern China, Prince of Wales Hospital, Hong Kong, China; and Timothy R. Rebbeck, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.0096DOI Listing
January 2016

Toward High-Precision Genomic Biomarkers: The Importance of Context.

J Thorac Oncol 2015 Sep;10(9):1237-1239

Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000633DOI Listing
September 2015

An eleven gene molecular signature for extra-capsular spread in oral squamous cell carcinoma serves as a prognosticator of outcome in patients without nodal metastases.

Oral Oncol 2015 Apr 2;51(4):355-62. Epub 2015 Jan 2.

Department of Surgical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore; Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore; Cancer Therapeutics Research Laboratory, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2014.12.012DOI Listing
April 2015

Carcinoma of unknown primary site.

N Engl J Med 2014 11;371(21):2039

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1411384DOI Listing
November 2014

Tongue carcinoma infrequently harbor common actionable genetic alterations.

BMC Cancer 2014 Sep 19;14:679. Epub 2014 Sep 19.

Cancer Therapeutics Research Laboratory, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177593PMC
September 2014

Targeting cancer stem cell plasticity through modulation of epidermal growth factor and insulin-like growth factor receptor signaling in head and neck squamous cell cancer.

Stem Cells Transl Med 2014 Sep 14;3(9):1055-65. Epub 2014 Jul 14.

Cancer Therapeutics Research Laboratory, Laboratory of Cancer Epigenome, Department of Medical Oncology, and Department of Surgical Oncology, National Cancer Centre Singapore, Singapore

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.5966/sctm.2013-0214
Publisher Site
http://dx.doi.org/10.5966/sctm.2013-0214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149297PMC
September 2014

Ceritinib in ALK-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Mar;370(13):1189-97

From Massachusetts General Hospital, Boston (A.T.S., J.A.E.); Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Fox Chase Cancer Center, Philadelphia (R.M.); National Cancer Center and Genome Institute of Singapore, Singapore (D.S.W.T.); Vall d'Hebron University, Barcelona (E.F.); University of Washington, Seattle (L.Q.M.C.); University of Colorado, Denver (D.R.C.); University Hospital KU Leuven, Leuven, Belgium (J.V.); Huntsman Cancer Institute, Salt Lake City (S.S.); Istituto Europeo di Oncologia (T.D.P.) and Istituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas (A.S.) - both in Milan; Memorial Sloan-Kettering Cancer Center, New York (G.J.R.); Peter MacCallum Cancer Center, Melbourne, VIC, Australia (B.J.S.); Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg, German Center for Lung Research (M.T.), and German Cancer Consortium (M.S.), Heidelberg, and University Duisburg-Essen, Essen (M.S.) - all in Germany; Princess Margaret Cancer Center, Toronto (G.L.); and Novartis Institutes for BioMedical Research, Cambridge, MA (Y.Y.L., M.G., A.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1311107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079055PMC
March 2014

Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.

Int J Cancer 2014 Sep 3;135(5):1092-100. Epub 2014 Apr 3.

Department of Medical Oncology, National Cancer Centre, Singapore; Cancer Therapeutics Research Laboratory, National Cancer Centre, Singapore; Cancer Stem Cell Biology, Genome Institute of Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28750DOI Listing
September 2014

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.

Cancer Chemother Pharmacol 2013 Dec 2;72(6):1213-22. Epub 2013 Oct 2.

Drug Development Unit, The Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2286-7DOI Listing
December 2013

Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.

J Clin Oncol 2013 May 1;31(14):e237-9. Epub 2013 Apr 1.

Department of Medical Oncology, National Cancer Center Singapore, 11 Hospital Dr, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.3937DOI Listing
May 2013

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.

Cancer 2012 Feb 26;118(4):1032-9. Epub 2011 Jul 26.

Johns Hopkins Singapore International Medical Centre, Singapore, Republic of Singapore.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.26372
Publisher Site
http://dx.doi.org/10.1002/cncr.26372DOI Listing
February 2012

Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma.

Leuk Lymphoma 2011 Aug 10;52(8):1509-16. Epub 2011 Jun 10.

Department of Medical Oncology, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.574752DOI Listing
August 2011

Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.

Eur J Cancer 2010 Aug 21;46(12):2166-77. Epub 2010 Apr 21.

Translational Cancer Therapeutics Laboratory, Cancer Research-UK, London Research Institute, London, United Kingdom.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980491000250
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2010.03.019DOI Listing
August 2010

Truth about ERCC1 in lung cancer.

J Clin Oncol 2010 Apr 16;28(10):e162; author reply e164. Epub 2010 Feb 16.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.6270DOI Listing
April 2010

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Cancer J 2009 Sep-Oct;15(5):406-20

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2009/10000/Biomarker
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0b013e3181bd0445DOI Listing
April 2010

Primary tracheal lymphoma causing respiratory failure.

J Thorac Oncol 2008 Aug;3(8):929-30

Department of Medical Oncology, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318180271dDOI Listing
August 2008

Coffee consumption and risk of type 2 diabetes mellitus.

Authors:
Daniel S W Tan

Lancet 2003 Feb;361(9358):702; author reply 703

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01406736031258
Publisher Site
http://dx.doi.org/10.1016/S0140-6736(03)12582-2DOI Listing
February 2003

Nucleolar localization of an isoform of the IGF-I precursor.

BMC Cell Biol 2002 Jul 2;3:17. Epub 2002 Jul 2.

Department of Endocrinology, St Bartholomew's Hospital, Queen Mary, Universityof London, United Kingdom.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC117215PMC
http://dx.doi.org/10.1186/1471-2121-3-17DOI Listing
July 2002